Bavaria Ind acquires Catalent's business

Bavaria Industriekapital, a German industrial holding company, has purchased Catalent Pharma Solutions' oral manufacturing business. Terms  of the transaction were not disclosed.

The Osny, France-based business provides current Good Manufacturing  Practice development and manufacturing services for hormonal and other  high-potent drugs in oral-dose forms that are either approved for  commercial marketing or in clinical development. The firm expects to  retain all employees associated with the business as of the closing, and  to continue to serve all existing customers. The purchased business will  become known as Osny Pharma.

Hans Magnus Andresen, managing director of Bavaria, said: "Bavaria is  extremely excited about this acquisition. We have been very impressed by  the management and operating teams in Osny and look forward to playing a  vital part in the continuation of the site's positive development. The  site will focus strongly on keeping its loyal customer base satisfied  and continuously optimize its production processes without losing its  keen eye on delivering top quality products. Osny Pharma SAS has  long-standing traditions in this industry and is ideally positioned for  continued growth - organically, as well as through additional  acquisitions."